英夫利昔单抗和CT-P13在PLANETAS和PLANETRAS主要及扩展研究中的免疫原性评估：实验室方法描述的效用 - Suppr

Suppr

超能文献

Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.

作者信息

Meacci Francesca, Manfredi Mariangela, Infantino Maria, Grossi Valentina, Benucci Maurizio

机构信息

Immunology and Allergology Laboratory, San Giovanni di Dio Hospital, Florence, Italy.

Rheumatology Unit, San Giovanni di Dio Hospital, Florence, Italy.

出版信息

Ann Rheum Dis. 2016 Oct;75(10):e62. doi: 10.1136/annrheumdis-2016-210078. Epub 2016 Jul 11.

DOI:10.1136/annrheumdis-2016-210078

PMID:27401744

Abstract

摘要

相似文献

Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.英夫利昔单抗和CT-P13在PLANETAS和PLANETRAS主要及扩展研究中的免疫原性评估：实验室方法描述的效用

Ann Rheum Dis. 2016 Oct;75(10):e62. doi: 10.1136/annrheumdis-2016-210078. Epub 2016 Jul 11.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.强直性脊柱炎患者从参比英夫利昔单抗转换为CT-P13与继续使用CT-P13的疗效及安全性比较：来自PLANETAS扩展研究的102周数据

Ann Rheum Dis. 2017 Feb;76(2):346-354. doi: 10.1136/annrheumdis-2015-208783. Epub 2016 Apr 26.

A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.一项关于英夫利昔单抗生物类似药 CT-P13 在类风湿关节炎和强直性脊柱炎患者中药物生存、安全性和有效性的 5 年回顾性分析。

Clin Drug Investig. 2020 Jun;40(6):541-553. doi: 10.1007/s40261-020-00907-5.

Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.单中心所有炎性关节炎患者从原研英夫利昔单抗系统性转换为生物类似药CT-P13的疗效、免疫原性及成本分析

Acta Reumatol Port. 2019 Oct-Dec;44(4):303-311.

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.通过患者报告的结局、安全性和药代动力学评估，CT-P13与对照英夫利昔单抗在强直性脊柱炎患者中的长期疗效相当：随机平行组PLANETAS研究的54周结果

Arthritis Res Ther. 2016 Jan 20;18:25. doi: 10.1186/s13075-016-0930-4.

Comparative effectiveness of the biosimilar CT-P13.生物类似药CT-P13的比较疗效

J Comp Eff Res. 2017 Nov;6(8):693-712. doi: 10.2217/cer-2017-0033. Epub 2017 Sep 12.

Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.生物类似药英夫利昔单抗（CT-P13）的临床试验分析以及与英夫利昔单抗参比药品历史临床研究的比较。

Expert Rev Clin Immunol. 2015;11 Suppl 1:S15-24. doi: 10.1586/1744666X.2015.1090314.

CT-P13: design, development, and place in therapy.CT-P13：设计、研发及在治疗中的地位。

Drug Des Devel Ther. 2017 Jun 6;11:1653-1661. doi: 10.2147/DDDT.S109852. eCollection 2017.

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.生物类似单克隆抗体研发进展：英夫利昔单抗生物类似药CT-P13在风湿性疾病治疗中的应用

Immunotherapy. 2015;7(2):73-87. doi: 10.2217/imt.14.109.

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.CT-P13（生物类似药英夫利昔单抗）在类风湿性关节炎患者中的疗效和安全性：在PLANETRA扩展研究中从参比英夫利昔单抗转换为CT-P13与继续使用CT-P13的比较

Ann Rheum Dis. 2017 Feb;76(2):355-363. doi: 10.1136/annrheumdis-2015-208786. Epub 2016 Apr 29.

引用本文的文献

Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity.在风湿病学中生物疗法的实验室监测：免疫原性的作用。

Ann Lab Med. 2020 Mar;40(2):101-113. doi: 10.3343/alm.2020.40.2.101.

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.脊柱关节炎患者从原研英夫利昔单抗转换为生物类似药英夫利昔单抗的安全性、有效性及免疫原性：一项为期6个月的真实世界观察性研究。

Immunol Res. 2017 Feb;65(1):419-422. doi: 10.1007/s12026-016-8843-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验